Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30258
Title: Large variation in radiation therapy fractionation for multiple myeloma in Australia.
Austin Authors: Ong, Wee Loon ;MacManus, Michael;Milne, Roger L;Foroudi, Farshad ;Millar, Jeremy L
Affiliation: Olivia Newton-John Cancer Wellness and Research Centre..
Central Clinical School, Monash University, Melbourne, Victoria, Australia..
School of Clinical Medicine, University of Cambridge, Cambridge, UK..
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia..
Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia..
Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia..
Precision Medicine, School of Clinical Sciences, Monash Health, Monash University, Melbourne, Victoria, Australia..
Alfred Health Radiation Oncology, Melbourne, Victoria, Australia..
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia..
Issue Date: 2023
Date: 2022
Publication information: Asia-Pacific Journal of Clinical Oncology 2023; 19(1)
Abstract: To evaluate the patterns of use of different radiation therapy (RT) fractionation for multiple myeloma (MM) bone disease. This is a population-based cohort of patients with MM who had RT between 2012 and 2017 as captured in the statewide Victorian Radiotherapy Minimum Data Set in Australia. Data linkage was performed to identify subsets of RT delivered within 3 months of death. RT fractionation was classified into four groups: single-fraction (SFRT), 2-5, 6-10, and > 10 fractions. Changes in RT fractionation use over time were evaluated with the Cochran-Armitage test for trend. Factors associated with RT fractionation were evaluated using multivariate logistic regressions. Nine hundred and sixty-seven courses of RT were delivered in 623 patients. The proportion of SFRT, 2-5, 6-10 and > 10 fractions RT was 18%, 47%, 28%, and 7%, respectively. There was an increase in the use of 2-5 fractions, from 48% in 2012 to 60% in 2017 (p-trend < .001), with corresponding decrease in the use of 6-10 fractions, from 26% in 2012 to 20% in 2017 (p-trend = .003). Nine percent (40/430) of RT courses at private institutions were SFRT, compared to 25% (135/537) in public institutions (p < .001). In multivariate analyses, treatment in private institution was the strongest predictor of multifraction RT use. SFRT use was more common closer to the end of life--18%, 14%, and 33% of RT within 2-3, 1-2, < 1 month of death, respectively. There is increasing use of shorter course RT (2-5 fractions) for MM over time. SFRT use remains low, with large variation in practice.
URI: https://ahro.austin.org.au/austinjspui/handle/1/30258
DOI: 10.1111/ajco.13783
ORCID: 0000-0001-6657-7193
0000-0001-8387-0965
Journal: Asia-Pacific journal of clinical oncology
PubMed URL: 35599450
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35599450/
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

48
checked on Dec 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.